SOAT1 and graft versus host disease: Despite the advanced clinical validation of JAK/STAT inhibitors in GVHD [reviewed by Assal and Mapara, (224)], few other agents of the Kinase-inhibitor group have also shown beneficial effect on GVHD in pre-clinical studies.